Compare CHNR & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHNR | CDT |
|---|---|---|
| Founded | N/A | 2019 |
| Country | China | United States |
| Employees | N/A | 4 |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 5.9M |
| IPO Year | 1996 | N/A |
| Metric | CHNR | CDT |
|---|---|---|
| Price | $3.94 | $0.49 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 45.1K | ★ 12.2M |
| Earning Date | 05-15-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.16 | $0.37 |
| 52 Week High | $8.20 | $11.00 |
| Indicator | CHNR | CDT |
|---|---|---|
| Relative Strength Index (RSI) | 43.45 | 35.59 |
| Support Level | $3.35 | N/A |
| Resistance Level | $4.12 | $0.73 |
| Average True Range (ATR) | 0.30 | 0.23 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 23.73 | 1.05 |
China Natural Resources Inc is engaged in exploration for lead, silver, and other metals in the Inner Mongolia Autonomous Region of the PRC and exploration of attractive opportunities in other sectors. The company has a single operating segment: exploration and mining.
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.